RUBYnanomed is a pioneering brand that specializes in non-invasive and real-time monitoring of cancer progression. Their flagship product, the RUBYchip TM, is a groundbreaking microfluidic-based device that allows for the isolation and analysis of circulating tumor cells (CTCs) through liquid biopsy, directly from blood samples. This innovative technology enables frequent monitoring of cancer progression in a minimally invasive and cost-efficient way.

With the RUBYchip TM, oncologists can detect and analyze the evolution of cancer subtype and therapeutic resistance mechanisms in each patient. This personalized approach provides valuable insights for designing tailored therapy plans, ensuring the best possible outcomes for cancer patients. RUBYnanomed was founded by three ambitious women who are passionate about science and technology.

Their mission is to make this cutting-edge technology available and accessible to every cancer patient as quickly as possible. With their commitment to innovation and patient well-being, RUBYnanomed is revolutionizing cancer monitoring and treatment. For more information and to stay updated with RUBYnanomed's latest developments, visit their website and explore their award-winning innovation